Market Research Logo

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2016

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2016’, provides an overview of the B-Cell Chronic Lymphocytic Leukemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia
  • The report reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved B-Cell Chronic Lymphocytic Leukemia therapeutics and enlists all their major and minor projects
  • The report assesses B-Cell Chronic Lymphocytic Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
B-Cell Chronic Lymphocytic Leukemia Overview
Therapeutics Development
Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Overview
Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis
B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Development by Companies
B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Investigation by Universities/Institutes
B-Cell Chronic Lymphocytic Leukemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
B-Cell Chronic Lymphocytic Leukemia - Products under Development by Companies
B-Cell Chronic Lymphocytic Leukemia - Products under Investigation by Universities/Institutes
B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development
AB Science SA
Aduro BioTech, Inc.
Amgen Inc.
Celgene Corporation
Cell Source, Inc.
Dynavax Technologies Corporation
Eisai Co., Ltd.
Elsalys Biotech SAS
F. Hoffmann-La Roche Ltd.
iDD biotech SAS
Immunomedics, Inc.
Johnson & Johnson
Juno Therapeutics Inc.
Lymphocyte Activation Technologies, S.A.
MedImmune, LLC
MEI Pharma, Inc.
Millennium Pharmaceuticals Inc
Molecular Templates Inc.
Noxxon Pharma AG
Ono Pharmaceutical Co., Ltd.
Regeneron Pharmaceuticals Inc
Sunesis Pharmaceuticals, Inc.
TheraMAB LLC
Unum Therapeutics, Inc.
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
202-b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-8779 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alemtuzumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alisertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-319 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BION-1301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Hematological Malignancies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD19 for B-Cell Malignancies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
durvalumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-7449 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDD-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDD-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-64052781 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lenalidomide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAT-303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ME-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mRNA ACTR + rituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-3724 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olaptesed pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-4059 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-1979 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SD-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNS-062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAB-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products
B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones
Featured News & Press Releases
Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement
Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2016
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by AB Science SA, H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Aduro BioTech, Inc., H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Amgen Inc., H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Celgene Corporation, H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Cell Source, Inc., H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Dynavax Technologies Corporation, H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Eisai Co., Ltd., H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Elsalys Biotech SAS, H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by iDD biotech SAS, H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics, Inc., H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Johnson & Johnson, H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Juno Therapeutics Inc., H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Lymphocyte Activation Technologies, S.A., H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by MedImmune, LLC, H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by MEI Pharma, Inc., H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Molecular Templates Inc., H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Noxxon Pharma AG, H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Sunesis Pharmaceuticals, Inc., H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by TheraMAB LLC, H2 2016
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Unum Therapeutics, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H2 2016
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects (Contd..1), H2 2016
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects (Contd..2), H2 2016
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2016
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report